Evaxion A/S: Financial statements 2012
CVR: 31762863
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
Evaxion A/S (CVR 31762863) has filed annual accounts for 2012. In 2012, the company reported revenue of DKK 1,374,684 and a net result of DKK 324,467. The profit margin was 23.6%. Equity in the 2012 report amounted to DKK 119,323. The solvency ratio was 10.1%.
- Revenue
- DKK 1,374,684
- Profit/Loss
- DKK 324,467
- Equity
- DKK 119,323
- Total Assets
- DKK 1,177,525
Official annual report
Keep an eye on Evaxion A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of February 15, 2012, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Evaxion A/S.
As of February 15, 2012, DKNF 387 ApS has stepped down as auditor of Evaxion A/S.
About Evaxion A/S
Evaxion A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2008. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named EVAXION BIOTECH A/S and EVAXION BIOTECH ApS. The management consists of Helen Katrina Tayton-Martin, Andreas Holm Mattsson and Thomas Frederik Schmidt. The board consists of Marianne Søgaard (chair), Jens Bitsch-Nørhave, Lars Holtug and Lars Aage Staal Wegner. The company is owned by BNY (Nominees) Limited (as nominee of The Bank of New York Mellon). The company has 24 employees (2018). In 2025, the company reported revenue of DKK 48,112,000 and a net result of DKK -51,489,000 compared with DKK -73,277,000 the year before. Equity in the 2025 report amounted to DKK 108,250,000.